WO2007051081B1 - Methods and compounds for preparing cc-1065 analogs - Google Patents

Methods and compounds for preparing cc-1065 analogs

Info

Publication number
WO2007051081B1
WO2007051081B1 PCT/US2006/060050 US2006060050W WO2007051081B1 WO 2007051081 B1 WO2007051081 B1 WO 2007051081B1 US 2006060050 W US2006060050 W US 2006060050W WO 2007051081 B1 WO2007051081 B1 WO 2007051081B1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
compound
alkyl
iii
Prior art date
Application number
PCT/US2006/060050
Other languages
French (fr)
Other versions
WO2007051081A1 (en
WO2007051081A8 (en
Inventor
Sanjeev Gangwar
Qian Zhang
Original Assignee
Medarex Inc
Sanjeev Gangwar
Qian Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006305842A priority Critical patent/AU2006305842B2/en
Priority to CN2006800491755A priority patent/CN101365679B/en
Priority to BRPI0619331-5A priority patent/BRPI0619331A2/en
Priority to ES06839458T priority patent/ES2375843T3/en
Priority to US12/090,445 priority patent/US7847105B2/en
Priority to AT06839458T priority patent/ATE534629T1/en
Priority to EP06839458A priority patent/EP1940789B1/en
Application filed by Medarex Inc, Sanjeev Gangwar, Qian Zhang filed Critical Medarex Inc
Priority to EA200801176A priority patent/EA015324B1/en
Priority to PL06839458T priority patent/PL1940789T3/en
Priority to DK06839458.4T priority patent/DK1940789T3/en
Priority to CA2627046A priority patent/CA2627046C/en
Priority to JP2008538132A priority patent/JP5116686B2/en
Publication of WO2007051081A1 publication Critical patent/WO2007051081A1/en
Publication of WO2007051081B1 publication Critical patent/WO2007051081B1/en
Priority to IL190971A priority patent/IL190971A/en
Priority to NO20082243A priority patent/NO20082243L/en
Priority to HK08110088.4A priority patent/HK1118549A1/en
Publication of WO2007051081A8 publication Critical patent/WO2007051081A8/en
Priority to HR20120058T priority patent/HRP20120058T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

A method of forming a CBI CC- 1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed.

Claims

AMENDED CLAIMS received by the International Bureau on 25 May 2007(25.05.2007)What is claimed as new and desired to be protected is:
1. A method of making a compound (I) or a salt thereof,
Figure imgf000002_0001
(I) wherein R1 and R2 are each independently H, alkyl, -C(O)OR', -C(O)NR'R", or a protecting group, wherein R' and R" are independently selected ii'om the group consisting of H, substituted alkyl, unsubstituted alkyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted lieterocycloalkyl, and unsubstituted heterocycloalkyl; R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy; and X is halogen, the method comprising: adding protecting groups R1 and R2 to a compound (II)
Figure imgf000002_0002
(II) to form a compound (III)
Figure imgf000002_0003
(III) wherein R3 is alkyl; and
AMENDED SHEET (ARTICLE 19)
45 generating a five membered ring comprising the amine nitrogen of compound (III).
2. The method of claim 1, wherein R3 is methyl.
3. The method of claim 1, wherein X is Cl or Br.
4. The method of claim 3, wherein X is Br.
5. The method of claim 1, wherein R1 and R2 are different protecting groups.
6. The method of claim 5, wherein adding R1 and R2 comprises adding
R1 to compound (II) to form compound (IIP)
Figure imgf000003_0001
(IIP) and replacing the protecting group R1 on the hydroxyl substituent with the protecting group R2 .
7. The method of claim 5, wherein R1' is tert-butyloxycEirbonyl.
8. The method of claim 7, wherein R2' is -CH2Ph.
9. The method of claim 1, wherein R1 and R2 are the same.
10. The method of claim I5 further comprising replacing R and R with hydrogen after generating the five membered ring.
11. The method of claim 1, wherein R1 and R1 are the same and R2 and R2 are the same.
AMENDED SHEET (ARTICLE 19)
46
12. The method of claim 1 , wherein generating the five nu :mbered ring comprises iodination of a carbon adjacent the amine substituent of compound (III) followed by alkylation using 1,3-dihalopropene.
13. A method of making a CBI CC- 1065 analog, or a pharmaceutically acceptable salt thereof, having the following formula:
Figure imgf000004_0001
wherein X is halo;
X1 and Z are each independently selected from O, S and NR8, wherein R8 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R , R4', R5 and R5' are members independently selected from the group consisting of H, substituted alkyl, unsubstituted alkyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted hetcrocycloalkyl, unsubstituted heterocycloalkyl, halogen, NO2, NR9R10, NC(O)R9, 0(J(O)NR9R10, OC(O)OR9, C(O)R9, SR9, OR9, CR9=NR10, and OCH2NR11R11', wherein R9 and R10 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituled or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, and substituted or unsubstituted peptidyl, or wherein R9 and R10 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and
R1 ' and R1 ' are each independently H or lower alkyl;
R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy; and
R7 is a member selected from the group consisting of H, substituted alkyl, unsubstituted alkyl, substituted heteroalkyl, unsubstituted heteroalkyl , diphosphates,
AMENDED SHEET (ARTICLE 19)
47 triphosphates, acyl, C(O)R12R13, C(O)OR12, C(O)NR12R13, P(O)(OR1 2)2, C(O)CHR12R13, SR12 and SiR12R13R14, wherein R12, R13, and R are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroailkyl and substituted or unsubstituted aryl, or wherein R12 and R13 together with the nitrogen or carbon atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms; the method comprising: adding protecting groups R1 and R2 to a compound (II)
Figure imgf000005_0001
(II) to form a compound (III)
Figure imgf000005_0002
(III) wherein R3 is alkyl; and generating a five membered ring comprising the amine nitrogen of compound (III); and adding a binding unit to compound (III), the binding unit comprising
Figure imgf000005_0003
14. The method of claim 13, wherein generating the five membered ring comprises iodination of a carbon adjacent the amine substituent of compound (III)
AMENDED SHEET (ARTICLE 19) followed by alkylalion using 1,3-dihalopropene prior to generating the five membered ring.
15. The method of claim 13, wherein adding the binding unit comprises removing the protecting group R1 '.
16. The method of claim 15, wherein adding the binding unit further comprises adding the binding unit to the amine substituent.
17. The method of claim 13, wherein R6 is H.
18. A compound of formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000006_0001
(I) wherein R1 and R2 are each independently H, alkyl, -C(O)OR', -C(O)NR3R", or a protecting group, wherein R' and R" are independently selected from, the group consisting of H, substituted alkyl, unsubstituted alkyl, substituted aiyl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted heterocycloalkyl, and unsubstituted heterocycloalkyl; and
Rό is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy.
19. The compound of claim 18, wherein R1 and R2 are different protecting groups.
20. The compound of claim 18, wherein the compound Js
AMENDED SHEET (ARTICLE 19)
49
Figure imgf000007_0001
AMENDED SHEET (ARTICLE 19)
50
PCT/US2006/060050 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs WO2007051081A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
PL06839458T PL1940789T3 (en) 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs
BRPI0619331-5A BRPI0619331A2 (en) 2005-10-26 2006-10-18 method for making a compound to prepare a cbi cc-1065 analog, method for making a cbi cc-1065 analog and compound
ES06839458T ES2375843T3 (en) 2005-10-26 2006-10-18 PROCEDURES AND COMPOUNDS FOR THE PREPARATION OF ANC? LOGOS OF CC-1065.
US12/090,445 US7847105B2 (en) 2005-10-26 2006-10-18 Methods and compounds for preparing CC-1065 analogs
AT06839458T ATE534629T1 (en) 2005-10-26 2006-10-18 METHOD AND COMPOUNDS FOR PRODUCING CC-1065 ANALOGUE
EP06839458A EP1940789B1 (en) 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs
DK06839458.4T DK1940789T3 (en) 2005-10-26 2006-10-18 Methods and Compounds for the Preparation of CC-1065 Analogs
EA200801176A EA015324B1 (en) 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs
CN2006800491755A CN101365679B (en) 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs
AU2006305842A AU2006305842B2 (en) 2005-10-26 2006-10-18 Methods and compounds for preparing CC-1065 analogs
CA2627046A CA2627046C (en) 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs
JP2008538132A JP5116686B2 (en) 2005-10-26 2006-10-18 Methods for preparing CC-1065 analogs and compounds for preparation
IL190971A IL190971A (en) 2005-10-26 2008-04-17 Method of making a tricyclic compound and a method of making a cbi cc-1065 analog
NO20082243A NO20082243L (en) 2005-10-26 2008-05-15 Methods and Compounds for Preparation of CC-1065 Analogs
HK08110088.4A HK1118549A1 (en) 2005-10-26 2008-09-11 Methods and compounds for preparing cc-1065 analogs
HR20120058T HRP20120058T1 (en) 2005-10-26 2012-01-19 Methods and compounds for preparing cc-1065 analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73080405P 2005-10-26 2005-10-26
US60/730,804 2005-10-26

Publications (3)

Publication Number Publication Date
WO2007051081A1 WO2007051081A1 (en) 2007-05-03
WO2007051081B1 true WO2007051081B1 (en) 2007-07-19
WO2007051081A8 WO2007051081A8 (en) 2010-12-16

Family

ID=37766648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/060050 WO2007051081A1 (en) 2005-10-26 2006-10-18 Methods and compounds for preparing cc-1065 analogs

Country Status (23)

Country Link
US (1) US7847105B2 (en)
EP (1) EP1940789B1 (en)
JP (1) JP5116686B2 (en)
KR (1) KR20080068084A (en)
CN (1) CN101365679B (en)
AT (1) ATE534629T1 (en)
AU (1) AU2006305842B2 (en)
BR (1) BRPI0619331A2 (en)
CA (1) CA2627046C (en)
CY (1) CY1112533T1 (en)
DK (1) DK1940789T3 (en)
EA (1) EA015324B1 (en)
ES (1) ES2375843T3 (en)
HK (1) HK1118549A1 (en)
HR (1) HRP20120058T1 (en)
IL (1) IL190971A (en)
NO (1) NO20082243L (en)
PL (1) PL1940789T3 (en)
PT (1) PT1940789E (en)
RS (1) RS52100B (en)
SI (1) SI1940789T1 (en)
WO (1) WO2007051081A1 (en)
ZA (1) ZA200804521B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2188311B1 (en) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2195017B1 (en) 2007-10-01 2014-10-22 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
BRPI0921687A8 (en) 2008-11-03 2022-11-08 Syntarga Bv COMPOUND, CONJUGATE, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A MAMMAL IN NEED THEREOF, AND, METHOD FOR TREATING OR PREVENTING A TUMOR IN A MAMMAL.
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
PT2403878T (en) 2009-03-05 2017-09-01 Squibb & Sons Llc Fully human antibodies specific to cadm1
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
ES2815678T3 (en) 2010-04-21 2021-03-30 Syntarga Bv Conjugates of CC-1065 Analogs and Bifunctional Linkers
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
LT2956173T (en) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
DK2948183T3 (en) 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv DUOCARMYCIN ADCS USED IN TREATMENT OF ENDOMETRY CANCER
CN105899235B (en) 2014-01-10 2019-08-30 斯索恩生物制药有限公司 Method for purifying the antibody-drug conjugates of CYS connection
LT3069735T (en) 2014-01-10 2018-06-11 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in the treatment of bladder cancer
AU2015231210B2 (en) 2014-03-20 2019-09-12 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CA2968382A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
PT3233912T (en) 2014-12-19 2021-08-09 Regenesance B V Antibodies that bind human c6 and uses thereof
ES2747386T3 (en) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Heteroarylene-linked benzodiazepine dimers, conjugates thereof and methods of preparation and use
WO2017053619A1 (en) 2015-09-23 2017-03-30 Bristrol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
EA201891121A1 (en) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
JP2019515677A (en) 2016-04-26 2019-06-13 アール.ピー.シェーラー テクノロジーズ エルエルシー Antibody conjugates and methods of making and using the same
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
KR102493853B1 (en) 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
MX2019009117A (en) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof.
CN110621337B (en) 2017-05-10 2021-11-09 浙江时迈药业有限公司 anti-LAG 3 human monoclonal antibodies and uses thereof
CN116333129A (en) 2017-05-25 2023-06-27 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN113164780A (en) 2018-10-10 2021-07-23 泰洛斯治疗公司 anti-LAP antibody variants and uses thereof
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020117627A1 (en) 2018-12-03 2020-06-11 Bristol-Myers Squibb Company Anti-ido antibody and uses thereof
CN109762067B (en) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 Antibodies that bind human Claudin18.2 and uses thereof
CN113396162A (en) 2019-01-22 2021-09-14 百时美施贵宝公司 Antibodies against IL-7R alpha subunit and uses thereof
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
EP3999541A1 (en) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
CN114945409A (en) 2020-01-13 2022-08-26 新免疫技术有限公司 Methods of treating tumors with combinations of IL-7 proteins and bispecific antibodies
US20230105029A1 (en) 2020-02-27 2023-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
CN114685669A (en) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 Antibodies that bind TROP2 and uses thereof
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4978757A (en) 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US4912227A (en) 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0271581B1 (en) 1986-04-17 1993-01-13 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
US5332837A (en) 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5773435A (en) 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US4994578A (en) 1987-11-27 1991-02-19 Meiji Seika Kaisha, Ltd. Certain anti-tumor duocarmycin antibiotics from streptomyces
US5147786A (en) 1988-04-22 1992-09-15 Monsanto Company Immunoassay for the detection of α-haloacetamides
JP2642165B2 (en) 1988-07-22 1997-08-20 協和醗酵工業株式会社 Novel DC-89 compound and method for producing the same
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (en) 1988-12-28 1997-04-09 協和醗酵工業株式会社 New substance DC113
JP2510335B2 (en) 1989-07-03 1996-06-26 協和醗酵工業株式会社 DC-88A derivative
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5495009A (en) 1989-10-24 1996-02-27 Gilead Sciences, Inc. Oligonucleotide analogs containing thioformacetal linkages
US5334528A (en) 1989-10-30 1994-08-02 The Regents Of The University Of California Monoclonal antibodies to cyclodiene insecticides and method for detecting the same
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0527189A1 (en) 1990-04-25 1993-02-17 PHARMACIA & UPJOHN COMPANY Novel cc-1065 analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69121334T2 (en) 1990-07-26 1997-03-20 Kyowa Hakko Kogyo Kk DC-89 derivatives as anti-tumor agents
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH0597853A (en) 1991-10-07 1993-04-20 Kyowa Hakko Kogyo Co Ltd Hydrobromic acid salt of dc-89 derivative
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DK0563475T3 (en) 1992-03-25 2000-09-18 Immunogen Inc Conjugates of Cell Binding Agents and Derivatives of CC-1065
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JP3514490B2 (en) 1992-08-21 2004-03-31 杏林製薬株式会社 Trifluoromethylpyrroloindole carboxylate derivative and method for producing the same
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
DE4314091A1 (en) 1993-04-29 1994-11-03 Boehringer Mannheim Gmbh Immunological detection method for triazines
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5786377A (en) 1993-11-19 1998-07-28 Universidad De Santiago De Compostela Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications
CA2165819C (en) 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
JPH07309761A (en) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd Method for stabilizing duocamycin derivative
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JP4157600B2 (en) 1994-08-19 2008-10-01 ラ レフィオン バロンネ COMPOUND, COMPOSITION FOR PREPARATION, DIAGNOSTIC DEVICE CONTAINING THEM, AND USE THEREOF
EP0786252A4 (en) 1994-09-30 1998-01-07 Kyowa Hakko Kogyo Kk Antitumor agent
CN1051552C (en) 1994-11-29 2000-04-19 杏林制药株式会社 Acrylamide derivatives and process for producing the same
WO1996035451A1 (en) 1995-05-10 1996-11-14 Kyowa Hakko Kogyo Co., Ltd. Novel toxin complex
US5686237A (en) 1995-06-05 1997-11-11 Al-Bayati; Mohammed A. S. Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5646298A (en) * 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1997012862A1 (en) * 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
CA2187969C (en) 1995-10-17 2006-05-30 Dale L. Boger A template for solution phase synthesis of combinatorial libraries
ES2195036T3 (en) 1995-12-22 2003-12-01 Bristol Myers Squibb Co RAMIFIED HYDRAZONE CONNECTORS.
US6143901A (en) 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
ES2244991T3 (en) * 1996-03-08 2005-12-16 The Scripps Research Institute ANALOGOSMCBI OF CC-1065 AND THE DUOCARMYCINS.
CA2255703A1 (en) * 1996-05-31 1997-12-04 Dale L. Boger Analogs of cc-1065 and the duocarmycins
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JPH1087666A (en) 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd Intermediate for producing duocarmycin sa and its derivative and production thereof
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1998043663A1 (en) 1997-03-28 1998-10-08 The Scripps Research Institute Sandramycin analogs
AU7274898A (en) 1997-05-07 1998-11-27 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
CA2290789A1 (en) 1997-05-22 1998-11-26 Dale L. Boger Analogs of duocarmycin and cc-1065
WO1999019298A1 (en) 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
AU1807999A (en) * 1997-12-08 1999-06-28 Scripps Research Institute, The Synthesis of cc-1065/duocarmycin analogs
JP3045706B1 (en) 1998-09-14 2000-05-29 科学技術振興事業団 Compound for alkylating a specific base sequence of DNA and method for synthesizing the same
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6909006B1 (en) * 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
ES2274823T3 (en) 1999-12-29 2007-06-01 Immunogen, Inc. COTOTOXIC AGENTS THAT INCLUDE DOXORRUBICINAS AND DAUNORRUBICINAS AND ITS THERAPEUTIC USE.
US6559125B1 (en) * 2000-01-28 2003-05-06 California Institute Of Technology Polyamide-alkylator conjugates and related products and method
ATE362940T1 (en) 2000-03-16 2007-06-15 Genesoft Inc CHARGED COMPOUNDS WITH A NUCLEIC ACID BINDING UNIT AND THEIR USES
JP4061819B2 (en) 2000-05-12 2008-03-19 独立行政法人科学技術振興機構 Method for synthesizing interstrand crosslinker
EP1294403A2 (en) 2000-06-14 2003-03-26 Corixa Corporation Tripeptide prodrug compounds
AU2001266853B2 (en) 2000-06-14 2005-02-17 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6762179B2 (en) 2001-05-31 2004-07-13 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
CN101671335A (en) 2001-05-31 2010-03-17 梅达莱克斯公司 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
AU2002316539C1 (en) 2001-06-11 2008-10-30 Medarex, Inc. CD10-activated prodrug compounds
CA2459308A1 (en) 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6534660B1 (en) * 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
WO2004005327A1 (en) 2002-07-09 2004-01-15 Morphochem Ag Komb Chemie Novel tubulysin analogues
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
US20050026987A1 (en) 2003-05-13 2005-02-03 The Scripps Research Institute CBI analogues of the duocarmycins and CC-1065
BRPI0510909A2 (en) * 2004-05-19 2008-12-16 Medarex Inc cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof

Also Published As

Publication number Publication date
ZA200804521B (en) 2009-04-29
IL190971A (en) 2013-02-28
CN101365679A (en) 2009-02-11
CA2627046A1 (en) 2007-05-03
WO2007051081A1 (en) 2007-05-03
AU2006305842B2 (en) 2011-11-03
PL1940789T3 (en) 2012-04-30
CA2627046C (en) 2015-09-15
CY1112533T1 (en) 2015-12-09
CN101365679B (en) 2012-11-14
JP2009513676A (en) 2009-04-02
EA015324B1 (en) 2011-06-30
PT1940789E (en) 2012-02-01
JP5116686B2 (en) 2013-01-09
HRP20120058T1 (en) 2012-02-29
IL190971A0 (en) 2008-12-29
RS52100B (en) 2012-06-30
ES2375843T3 (en) 2012-03-06
SI1940789T1 (en) 2012-03-30
NO20082243L (en) 2008-07-21
EA200801176A1 (en) 2009-02-27
DK1940789T3 (en) 2012-03-19
AU2006305842A1 (en) 2007-05-03
EP1940789A1 (en) 2008-07-09
US20080281102A1 (en) 2008-11-13
BRPI0619331A2 (en) 2011-09-27
US7847105B2 (en) 2010-12-07
HK1118549A1 (en) 2009-02-13
ATE534629T1 (en) 2011-12-15
KR20080068084A (en) 2008-07-22
WO2007051081A8 (en) 2010-12-16
EP1940789B1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
WO2007051081B1 (en) Methods and compounds for preparing cc-1065 analogs
WO2006084030B1 (en) Small-molecule hsp90 inhibitors
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
EP1094065A3 (en) Cucurbituril derivatives, their preparation methods and uses
JP2008538381A5 (en)
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
RU92004336A (en) WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS
ATE287393T1 (en) CYCLOALKENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO2004066919A3 (en) Synthesis of 4amino-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines
JP2004131511A5 (en)
MX2009003927A (en) Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes.
WO2007074491B1 (en) HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
JP2008545864A5 (en)
IL169368A0 (en) Cyclization process for substituted benzothiazole derivatives
UA86013C2 (en) Aryl alkyl carbamate derivatives production and use thereof in therapy
EP1279665A3 (en) A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
EP1475094B8 (en) Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
GB9825554D0 (en) Novel Compounds
AR026222A1 (en) COMPOUNDS DERIVED FROM ANTRANILIC ACID
EP2511274A3 (en) Polyamine derivative
ES2167869T3 (en) PROCEDURE TO PREPARE NICOTINIC ACIDS.
JP2006176509A5 (en)
ES8500941A1 (en) 2-Cyano imidazopyridine derivatives, their preparation and use as fungicides.
EP0404197A3 (en) Arylalkylamine derivatives
JP2005520805A5 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680049175.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12090445

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 190971

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2627046

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008538132

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005438

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1744/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006305842

Country of ref document: AU

Ref document number: 567861

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006839458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087011981

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006305842

Country of ref document: AU

Date of ref document: 20061018

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200801176

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0619331

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080425

WWE Wipo information: entry into national phase

Ref document number: P-2012/0009

Country of ref document: RS